The goal as everyone knows, is to buy good stocks at a discount and sell-short overvalued stocks when they are at a premium. I have a background in business and deal with internal models, analysis, sales pitches and ad information daily. In my downtime, I am enthusiastic about the markets highs, lows and volatility. I believe in real lags between market and business reactions, with the former often in advance of the latter, and vice versa. I look to call manic enthusiasm with a distinct opportunity to go short. A change in sentiment is all it takes. I research fundamentals while scavenging for value.
I work for a government agency that actively monitors global financial markets. I have expertise in derivatives, traded products, securitizations, bonds, and equities. I also have experience with wealth management and corporate trust.
My personal investment preference is long-term buy & hold with a macro focus.
My opinions are my own and I do not express any views of the agency I work for.
I write about growth industries focusing on their best stock buys on Seeking AlphaConsultant, business management and development.
Former President of Sappanos Decorating Centers, Chicago, with more than 70 employees. Sold in 2010. Sold all our properties in excess of $10m.
Former Research and Teaching Fellow, Harvard and Assoc. Professor Tufts Medical School.
Currently teach business and politics at university in Tel Aviv, write a column for the Jerusalem Post in Business and Finance, and do business management and development consulting to start-ups and struggling companies.
Abdalla Al-ayrot is a value investor with a long time horizon. I tend to focus on misunderstood and/or under-followed companies where i believe there are a great amount of value that the market is yet to price in. Some people prefer to buy $1 for 50-60 cents, i usually buy $1 for 20-35 cents.
I have managed money for 5 years, with industry leading results, which i think is a direct result of my extensive and innovative research process.
I have also founded Ayrot, which you can read more about below.
Alan Brochstein, CFA, was the first investment professional to devote himself to sharing his observations about the cannabis industry from an investor's perspective publicly. He runs 420 Investor, a subscription-based due diligence platform for investors interested in the publicly-traded cannabis stocks and is also the founder of New Cannabis Ventures, a content aggregation site focused on investors and entrepreneurs in the cannabis industry.
Alan has worked in the securities industry since 1986, primarily with the responsibility for managing investments in institutional environments until he founded AB Analytical Services in 2007 in order to provide independent research and consulting to registered investment advisors. In addition to advising several different hedge funds and investment managers, including Friedberg Investment Management, where he participated as a member of its investment management committee, Alan was also a senior analyst for the independent research firm Management CV. In 2008, he began providing a first-of-its-kind subscription-based service for individual investors, Invest By Model, which offered two different portfolios that investors could replicate in their own accounts for $20 per month. Alan also offered The Analytical Trader at Marketfy, where he used fundamental and technical analysis in a disciplined process to offer specific trade ideas geared towards swing traders.
Alan launched www.420Investor.com in late 2013 as the premier source of information for "Green Rush" investors seeking to capitalize on the proliferation of legalized medical and recreational cannabis. In March 2014, Alan, who is a member of the National Cannabis Industry Association, began to focus solely on the cannabis sector. He launched www.NewCannabisVentures.com in late 2015.
You can follow Alan on Facebook (www.facebook.com/420investor) or on Twitter (https://twitter.com/Invest420). Alan also moderates a large LinkedIn group focused on the cannabis industry, Cannabis Investors & Entrepreneurs (https://www.linkedin.com/groups/6523904)
Tom Shaughnessy is owner of SecretCaps.com, an independent investor and analyst. He has been investing in the stock market since the age of twelve. His style is comprehensive and includes multi-layered research on a concentrated set of stocks. Tom enjoys constructive dialogue regarding various investment ideas and theories.
Tom enjoys intensive research on prospective investments. This includes valuation estimates and modeling, CEO and management interviews, product and expansion overviews, future prospects, financial analysis and the current state of affairs at the company. Moreover, Tom's articles have a focus on micro-cap companies whose potential have flown under the radar.
In his leisure time Tom enjoys playing racquetball on a competitive level.
I am a Master of Financial Engineering student at UC Berkeley with a bachelor in Engineering Science, Applied Physics taking a quantitative approach to investing and trading.
I was the portfolio director at Capital Investments at Berkeley, a student run hedge-fund. My strategies are centered around risk management, market hedging and the financial instruments that I primarily use are equities, fixed income assets and options.
Find me on LNKD: http://www.linkedin.com/pub/john-gay/41/201/653
Henry W. Schacht, CFA is the founder of Schacht Value Investors, an investment management firm. He earned his MBA at the University Of Chicago Graduate School of Business and a degree in finance from the University of Notre Dame.
Mr. Roche is the founder of Orcam Financial Group, LLC, a low fee financial services firm based in San Diego, CA as well as the founder of the popular financial website Pragmatic Capitalism (some articles from Pragmatic Capitalism get syndicated on Seeking Alpha so please see the full site if you don't want to miss articles by Mr. Roche).
Orcam Financial Group, LLC (www.orcamgroup.com) is a low fee financial services firm offering asset management, personal advisory, consulting and educational services. Pragmatic Capitalism (http://pragcap.com) was founded by Cullen Roche in the midst of the financial crisis of 2008. Mr. Roche foresaw many of the events that led up to the crisis and felt that the government was slow to react and when it did finally react, responded with the wrong medicine.
Mr. Roche's primary areas of expertise include global macro portfolio construction, quantitative risk management, monetary economics and behavioral finance. Prior to establishing his own business, Mr. Roche worked at Merrill Lynch Global Wealth Management where he worked on a team overseeing $500MM+ in assets under management. Upon leaving Merrill Lynch, Mr. Roche managed a private investment partnership for 7 years generating substantial positive alpha (high risk adjusted returns) without a single negative year of returns. He has since transitioned back to retail asset management to better serve the much needed low fee retail space with sophisticated but simple asset management and financial planning services.
Mr. Roche is also a prolific writer. In addition to the daily musings on his website, he is the author of the popular book “Pragmatic Capitalism: What Every Investor Needs to Know About Money and Finance” as well as “Understanding the Modern Monetary System”, one of the top 10 all-time most downloaded research papers on the SSRN academic research network. He was named one of the “Top Wall Street Economists, Experts and Opinion Leaders” of 2011 by Wall Street Economists and was named one of the “101 Best Finance People” by Business Insider where he was described as “one of the most influential economic thinkers today.” In 2015 Mr. Roche was named one of the “40 Under 40” most influential people in finance by InvestmentNews. He is regularly cited in the Wall Street Journal, on CNBC and in the Financial Times.
Mr. Roche is a Georgetown University alumnus, growing up in the DC area and now living in Southern California with his wife Erica, troublesome collie Cal and 4 irritable laying hens. In addition to being a financial dork Cullen is an avid outdoorsman, mediocre gardener, proficient complex carbohydrate consumer (i.e., loves brownies and cake) and finisher of one of the most difficult IRONMAN races at Cabo in 2015.
Philip Runfeld single-handedly founded and operated companies grossing nearly a million dollars a year, prior to becoming a sought after business consultant to some of the country’s leading Fortune 500 companies, such as Disney, Marriott International and DuPont Chemical. Certified by the U.S. Department of Labor, State Professional Boards, and National Organizations to develop and provide highly specialized training programs, Mr. Runfeldt is also qualified to teach Economics, Political History, Quality Management and Psychology. He has been a special instructor to students at Major Universities throughout the Southeastern United States and currently holds a “lifetime” professorship at 17 colleges. Mr. Runfeldt also provides consultation and instruction to municipalities, counties, state and federal governmental agencies, as well as expert testimony in court cases. Mr. Runfeldt has been a private investor for over 20 years and in comparison to private and professional money managers is ranked as one of the top investors in the country, according to Covestor.Com. As a current Board Certified Behavioral Analyst, Mr. Runfeldt applies the principles of Behavioral Analysis to how Traders perform (or not) and is an active Traders Coach. As cofounder of TapeBeat.Com, Mr. Runfeldt thoroughly believes that Investors can develop the skill set and follow simple steps to make “Each Trade Better”.
Disclaimer: This blog is an expression of an opinion on a particular company or matter. The author is not a financial advisor or professional analyst. This is not a solicitation to trade any security. Although we try our best on providing accurate information, the comments made in the blogs or articles should be considered only as opinion and should not be considered as current or as absolute fact. All investors are strongly encouraged to not rely entirely on any single opinion and perform their own due diligence when investing. Investing in equities includes considerable risk, and investors should be prepared for the risk of capital loss.
Rich Steffens has grown up in New Jersey, is a successful businessman, and follows social media trends amongst life science and biotech companies. His family is deeply influenced by the ill effects of diabetes, and is a kidney donor to his older sister. His area of interests also includes cancer immunotherapy, which he started writing about in 2008. Rich jokes that he is one of the world's slowest marathon runners, and he runs with MSKCCs Fred's Team to support cancer research, raising over $20,000 in ten years to support MSKCCs efforts.
Rich states- I am not qualified to offer investment or medical advice, and make no claims that I am an expert in these areas. I seek to share and learn.
Chad Brand is the founder and President of Peridot Capital Management LLC, a money management firm that provides investment management services to individuals and their families. Chad also publishes a blog which has been named one of the best investment-related blogs by many industry sources including Forbes, Capital Magazine, 24/7 Wall Street, and Daily Reckoning.
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 35 years executive experience including Abbott and JNJ and has been involved three successful start-ups. Before starting Raygent and other companies he was also a Technology Transfer Officer at UCLA. He has a B.S. from Penn State University and an MBA from Rutgers University.
His WEB site at www.raygent.com is currently focused in biopharmaceuticals, genomics and clinical diagnostics . Mr. Raynovich has extensive expertise in marketing and product development and provides business development consulting to early stage companies in biotechnology, diagnostics and imaging.
The Rayno Life Science Portfolio was published on www.raygent.com and other trade media.
Articles have been published on the following topics: Alzheimer Disease,Biomarkers, Genomics,Molecular Diagnostics, Oncology Drugs, Personalized Medicine, Targeted Therapy, Technology Trends, H1N1 and Government Policy on biotechnology.
The Life Science Portfolio is up over 80% over a 24 mo. period as of 5/30/14and among the life science portfolio winners are ABAX, ALXN, AMRI, BIIB, CBST, GPRO, ILMN, QDEL,REGN, SGEN, and VPHM.
John received his PhD in chemistry in the research group of Nobel Laureate Donald Cram in 1987 and his MBA from the Anderson School of Management at UCLA in 2009. His research career spans 16 years performing drug discovery research in metabolic diseases, cancer, HIV infection, antibacterials, and Alzheimer's disease. In 2011 John joined Sagient Research Systems as a Biotechnology Analyst. In 2013 he joined Zack's Small Cap Research as an Analyst.
On Twitter: @johntuckerphd
As John is neither licensed nor qualified to act as an investment advisor, his articles are written for discussion purposes only and should not be construed as investment advice. He makes a reasonable effort to avoid misstatements of fact, but advises all investors to consult primary sources prior to making an investment.
Nutritionist/MD/Biotech investor. I have little time to discuss the general market, anything I cannot change or other irrelevant topics that dominate seekingalpha and are the products of its top 100 members. I put my money where my mouth is and adhere to sound DD. Capitalism favors the bold and I intend to honor that. For any naysayers I'll leave the 15% yearly gains to you and you can leave the world to me. Embers will be the only thing left in my path.
Disclaimer: This blog is an expression of my opinion on a particular company or matter. I am not a financial advisor or professional analyst. This is not a solicitation to trade any security. Although I rely on company approved public documents and make all reasonable efforts to confirm the accuracy of my statements, the comments made in my articles should be considered only as opinion and should not be considered as current or as absolute fact. All investors are strongly encouraged to not rely entirely on any single opinion and perform their own due diligence when investing. Investing in equities includes considerable risk, and investors should be prepared for the risk of capital loss.
EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.
The founding members of Chimera Research Group have over 50 years of combined experience in the biotech and pharmaceutical sector. Their experience includes work at Investment Banks, Hedge Funds, Pharmaceutical Companies, top-tier Universities, and the U.S. Food and Drug Administration (FDA). Their published work includes freelance and editorial contributions both print and on-line, clinical and medical research, books and tutorials, as well as contributions to on-line social media. Through these and other activities they were able to collaborate and connect amongst themselves to establish this cadre of like-minded biotech/pharma trading and investing aficionados.
The Team includes:
Chief Scientific Analyst - Jason Chew
Chief Research Analyst - Patrick Crutcher
Chief Medical Analyst - Dr. Tro Kalayjian
CEO & Trading Analyst - Tony Pelz
Research Analyst - Dr. Andrew Goodwin
Research Analyst - Dr. Juan Pedro Rodríguez Serrate
Technical Analyst - Joe Gantoss
Research Analyst - Dr. Steven Murphy
I have worked in an executive financial capacity (CFO) for more than 25 years. In 2005, I became a serious student of the market to gain a better understanding of successful investing/trading. I began my blog, The Perplexed Investor, to provide an honest narrative of my process. My blog and my posts are intended to have heuristic (and perhaps some entertainment or schandenfreudic) value and should never to be (mis)construed as having the intent of providing readers with investment/trading advice. I put my blog on permanent hiatus, back in 2011 to get some perspective, and concentrate on some needful things in my life.
My investing and writing are primarily focussed on macro areas such as currencies, commodities, global investing, and geopolitics. I also closely monitor technology. I generally have a medium to longer-term investment horizon.
I encourage you to review the track record of my published articles both here at Seeking Alpha and at The Business Insider. I publish additional content available exclusively at www.polycapitalist.com.
Mike Havrilla is a former pharmacist (retail and home infusion settings), biotech stock trader, and writer with experience that includes full-time online trading since 2009, working as a full-time pharmacist from 2004-2009, and writing for investors since 2007. Mike holds Doctor of Pharmacy (PharmD) and Bachelor of Science (Biology) degrees from the University of Pittsburgh and worked in the pharmaceutical industry for Wyeth prior to pharmacy school. He is also an avid runner and has completed over 20 marathons with a personal best time under three hours for the 26.2 mile race and under 80 minutes for the half marathon. Mike merged his former publishing business with BioRunUp.com / Mark Messier in October 2010, creating a new online biotech stock research and trading subscription service.
The Burrill Report is written for everyone who wants to understand how biotechnology operates as a business. Each month the publication focuses on the health of the industry and the strategies that will be needed to be successful. It provides actionable market intelligence on the latest global developments and trends in the life sciences industry. Available monthly, subscribers also benefit from monthly and quarterly market financial and business statistics on:
- Public companies
- venture financings
- Project Runway – Follow the global life sciences companies filing for and completing their IPOs – and their post market performances
- Clinical Trials successes and failures
- M&A and Partnering deals
- Periodic country features on Canada, Europe and emerging countries such as China & India.
In addition, BR provides in-depth coverage on specific sectors of life sciences including: Personalized Medicine; Diagnostics, Medical Devices and Biogreentech (Ag-Bio and Biofuels/Bioenergy). Through weekly Burrill Indices, the progress and prospects of biotech companies by size, from small through to blue-chip are also tracked.
Visit: The Burrill Report to obtain your sample issue (http://www.burrillreport.com/)
James Hill is a clinical assistant professor of radiology at the University of Southern California Medical School, and a patent lawyer and partner at McDermott Will & Emery.
Although he relies on publicly available information and makes reasonable efforts to confirm its accuracy, all comments made in his blog posts and articles should be considered only opinion.
Nothing in these posts or articles constitutes legal, medical, or investment advice. Always do your own due diligence and confirm all information yourself.
Mr. Becker has more than 15-years of experience as a serial entrepreneur, C-level industry executive, drug developer, Wall Street securities analyst and registered financial advisor. He is also an online communications pioneer, popular blogger, and a sought-after speaker at industry events.
Before establishing MD Becker Partners LLC (www.mdbpartners.com) in 2008, he served as president, chief executive officer, and member of the Board of Directors for several publicly-traded biotechnology companies including commercial-stage Cytogen Corporation (acquired by EUSA Pharma) and development-stage VioQuest Pharmaceuticals, Inc.
While at Cytogen, Mr. Becker held positions of increasing responsibility, including Vice President of Business Development, Industry Relations, Investor Relations and Chief Executive Officer of AxCell Biosciences, a subsidiary of Cytogen focused on signal transduction pathways. During his tenure at Cytogen, Mr. Becker raised in excess of $130 million in new capital through both public offerings and private placements and in-licensed Caphosol(c), a topical oral agent and prescription medical device for the treatment of oral mucositis and xerostomia.
Prior to joining Cytogen, Mr. Becker was with Wayne Hummer Investments LLC, a Chicago-based regional brokerage firm, where he held senior positions as a biotechnology securities analyst, financial advisor and portfolio manager. He was also the founder and Executive Editor of Beck on Biotech, a monthly biotechnology investment newsletter published from July 1998 through March 2001. Mr. Becker was previously with Kidder, Peabody & Co., Gruntal & Co., L.L.C., and Kemper Securities. He has previously held the following financial licenses: Series 7 (Registered Representative), Series 16 (Securities Analyst), Series 63 (Uniform Securities Agent) and Series 65 (Registered Investment Advisor).
Mr. Becker plays an active leadership role as an advocate for the biotechnology industry. He is past Chairman and member of the board of trustees with BioNJ, which is New Jersey's trade association for biotechnology companies, and is currently a member of BioNJ, Pennsylvania Bio, the New Jersey Technology Council (NJTC), and the Pharmaceutical Consulting Consortium, Inc. (PCCI). Mr. Becker placed as a biotechnology/life sciences finalist for the Ernst & Young Entrepreneur of the Year award in both 2004 and 2005 and was listed in BusinessWeek's "CEO's 40 and Under" article in December 2006. He attended DePaul University in Chicago, Illinois.
MD Becker Partners newsletter site can be found at: http://lifesciencedigest.com
Douglas Krohn is a physician in private practice who provides biotechnology analysis. Dr. Krohn employs an evidence-based, peer-reviewed approach to his evaluation of pipeline biotechnology products. He is a graduate of the Albert Einstein College of Medicine, completed his pediatric residency at Montefiore Medical Center in the Bronx, and is a former columnist for The Cornell Daily Sun.
M.E. Garza is one of the founders of the biotech and healthcare sector news portal BioMedReports.com. He believes in getting the news from credible sources on the street and often reaches out to CEOs and newsmakers directly for interviews and discussions about their companies. Since he began publishing in 2008, Garza has built a reputation as a writer and reporter who can move markets. His track record for accurately reporting rumors and alerting readers about developments in the biotech/healthcare sector is unmatched during that time.
I am an attorney in Baltimore, Md., representing children with lead poisoning. I have been investing in biotech for over a decade.
I have an A.B. from Vassar College '76, Phi Beta Kappa; J.D. from Duke Law School '79; M.S. from Johns Hopkins University '08.